The global predictive genetic testing & consumer/wellness genomics market was valued at USD 2.24 billion in 2015. Shifting attention of federal regulatory agencies due to the rising public health concerns for the safety, validity, and effectiveness of genetic tests is anticipated to boost growth over the forecast period.
Comprehensive end-to-end solutions are not feasible; thus novel partnership models are coming into existence in this sector. Most of the companies operating in the genomics market are unable to provide end-to-end solutions, which pronounces the need for partnerships in order to gain the market share.
Germany wellness genomics market, by application, 2013 - 2025 (USD Million)
These partnerships include the partnerships within the government organizations and participants, diagnostic laboratories and big pharma companies, other prominent vendors and operating entities, collaboration with the health system, hospital or clinical research institution.
Efficient delivery of precision medicine through the collaborations is anticipated to drive industrial growth significantly. For instance, Syapse’s efforts with Intermountain Healthcare enables health systems in leveraging actionable insights from genomic data to personalize oncology treatment plans.
Availability of the niche, fragmented point-solutions across the genomics value chain is anticipated to propel growth over the forecast period. Predictive testing and consumer genomics is mostly implemented on the principle pf next generation sequencing.
There is substantial demand for a completely outsourced diagnostic solution, and many companies are engaged in the provision of a bundled sample-to-insight services. The majority of firms are providing ‘sequencing-as-a-service’, often relying on Illumina’s Next Generation Sequencing (NGS) technology for the process itself.
Test Type Insights
Presymptomatic and predispositional diagnosis have taken an ever-increasing role in clinical practice and translational research for the neurodegenerative diseases over the last two decades. Accurate and early identification of disease or hereditary risk aids in reduction of morbidity and mortality through screening, observation, and early treatment or prevention.
R&D carried out in the gene susceptibility testing for the construction of the evidence base to define optimal management of individuals who carry mutations in cancer susceptibility genes is expected to boost growth in genomics driven cancer medicine
Availability of multigene panels enables detection of different gene mutations; and more variants of uncertain significance, which may or may not be clinically actionable. The aforementioned fact is anticipated to accelerate the adoption of susceptibility tests for cancer and other diseases.
The ‘predict and prevent’ paradigm which leads to the related idea that the earlier you catch it, the better off you are likely to be is expected to drive awareness amongst the population about screening programs and lead to revenue generation.
Predictive genetic testing & consumer/wellness genomics market, by region, 2015 (USD Million)
About 5-10% of ovarian and breast cancers are resultant of the mutation inherited in the BRCA1 or BRCA2 gene. Prediction tests for hereditary non-polyposis colon cancer, can be useful to identify those at increased risk.
In 2015, the predictive genetic cardiovascular screening has occupied a market share of 16.8% closely following oncological screening tests. Revenue flow is expected to witness considerable growth in the forecast years owing to the benefits of preventive measures that these tests can aid in taking.
Innovations in the preventive medications for cholesterol reduction or prevention by targeting the new mechanisms that affect cardiac health are factors that are expected to drive this segment over the coming years.
About seventy-two companies have been identified that are engaged in nutrigenomics. This number seems likely to increase as the market space remains largely unregulated and recent searches have identified a number of new companies in this area.
North America captured the largest share in 2015 in terms of revenue in the global prediction based genetic diagnosis industry. Presence of key players that continue to undertake initiatives for enhancement of their direct-to-consumer & wellness genomic testing offerings can be attributed for estimated share.
Furthermore, U.S. companies are holding several patents which pronounces their growth. For instance, Myriad Genetics Inc (Myriad) holds patents for isolated genetic materials involved in ovarian & breast cancer diagnosis.
Growing awareness amongst Asian population pertaining to availability of predictive tests for determination of elevated risk of chronic diseases occurrence is anticipated to accelerate the growth of Asia Pacific market.
Some of the prominent players operating in this vertical include Illumina, Inc, BGI, Genesis Genetics, Myriad Genetics, Inc, 23andMe, Inc, Color Genomics Inc., Pathway Genomics, and ARUP Laboratories.
These entities are engaged in different forms of partnership within the consumer genomics industry. These include partnership of operating company with another vendor or the company from different sector.
For instance, in March 2016, 23andMe integrated its software with Apple’s Research Kit app. This enables the consumers to share their genetic information with researchers.
Base year for estimation
Actual estimates/Historical data
2013 - 2015
2016 - 2025
Revenue in USD Million and CAGR from 2016 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
Segments Covered in the Report
This report forecasts revenue growth at regional & country level and provides an analysis on the latest trends and opportunities in each of the sub-segments from 2013 to 2025. For the purpose of this study, Grand View Research has segmented the predictive genetic testing & consumer/wellness genomic market on the basis of test type, application, and country:
Test Type Outlook (Revenue, USD Million; 2013-2025)
Genetic Susceptibility Test
Application Outlook (Revenue, USD Million; 2013-2025)
Predictive Genetic Testing & Consumer Genomics
Breast & Ovarian Cancer
Diabetic Screening & Monitoring
Parkinsonism / Alzheimer’s Disease
Urologic screening/ Prostate cancer screening
Orthopedic & Musculoskeletal
Other cancer screening
Skin & Metabolism Genetics
Regional Outlook (Revenue, USD Million; 2013-2025)
Middle East and Africa (MEA)
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.